Fluidr / GE Healthcare's "GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc. " set

N 0 B 1.6K C 0 E Oct 14, 2010 F Oct 22, 2010

DESCRIPTION
COMMENT
O
L
M

Advanced tests like fluorescence in situ hybridization (FISH) help determine prognosis for lymphoma/leukemia patients. In this instance, CLL is detected

Tags: cancer pathology GE Healthcare

GE Healthcare to Acquire Clarient Inc.

N 1 B 1.2K C 0 E Oct 14, 2010 F Oct 22, 2010

DESCRIPTION
COMMENT
O
L
M

Estrogen receptor and progesterone receptor over-expression helps detect whether a patient is eligible for Tamoxifen® therapy for breast cancer

Tags: cancer pathology GE Healthcare

GE Healthcare to Acquire Clarient Inc.

N 1 B 1.5K C 0 E Oct 15, 2010 F Oct 22, 2010

DESCRIPTION
COMMENT
O
L
M

HER2 staining can help qualify patients for Herceptin® therapy. This can be detected with tests such as fluorescence in situ hybridization (FISH) or Immunohistochemistry (IHC) in individual cells using digital imaging microscopy

Tags: cancer pathology GE Healthcare

GE Healthcare to Acquire Clarient Inc.

N 0 B 1.2K C 0 E Oct 14, 2010 F Oct 22, 2010

DESCRIPTION
COMMENT
O
L
M

Tags: cancer pathology GE Healthcare

GE Healthcare to Acquire Clarient Inc.

N 0 B 2.2K C 0 E Oct 14, 2010 F Oct 22, 2010

DESCRIPTION
COMMENT
O
L
M

Tags: cancer pathology GE Healthcare